Featured

Status

Health Topics

Any Category
Clear Filters

Search Clinical Trials

400 Results
Completed
H-22411: BOTOX® for Peyronie's Disease
Treatments for this disease have been limited and often unsuccessful. The goal of treatment is to reduce pain and maintain sexual function. Oral medicines that prevent plaque formation and promote …
Withdrawn
A Study of Bevacizumab to Prevent Malignant Ascites
All subjects will be treated with an intravenous infusion of the experimental drug (Bevacizumab 15 mg/kg) every 3 weeks for a total of twelve (12) weeks on study. The primary …
Baylor Role: Lead Sponsor
Terminated
Evaluating the Use of Exenatide in People With Type 2 Diabetes and Diastolic Heart Failure
Diastolic heart failure is a life-threatening condition that occurs when the ventricles of the heart become stiff and do not fully relax, preventing the heart from properly filling with blood. …
Baylor Role: Lead Sponsor
Completed
Nepicastat for Posttraumatic Stress Disorder (PTSD) in OIF/OEF Veterans
HYPOTHESES Primary Hypothesis: Compared to placebo treatment, nepicastat-treated OIF/OEF veterans with PTSD will have significantly reduced PTSD hyperarousal symptoms as defined by the Clinician Administered PTSD Scale [CAPS], subscale D …
Baylor Role: Collaborator
Completed
Nitric Oxide Production in MELAS Syndrome
What does the study involve? Individuals with MELAS syndrome will be admitted twice to the General Clinical Research Center (GCRC) at Texas Children's Hospital. Each time they will stay for …
Baylor Role: Lead Sponsor
Completed
Rivastigmine as a Treatment for Methamphetamine Dependence
We recently completed a double-blind placebo-controlled human laboratory study demonstrating that treatment with a low dose of the acetylcholinesterase (AChE) inhibitor rivastigmine reduced methamphetamine (METH)-induced craving (see Preliminary Studies, Fig. …
Baylor Role: Lead Sponsor
Completed
The Effect of Byetta and Symlin on Post-meal Meal Blood Sugar Levels in Children With Type 2 Diabetes
A large study in people with type 2 diabetes (T2DM) showed that lowering blood sugars stopped or delayed the occurrence of health problems. As a result of the study, treatment …
Baylor Role: Lead Sponsor
Completed
Prevention of Recurrent Infections Caused by Community Acquired Staphylococcus Aureus (CA-SA) in Children
In many areas of the United States, methicillin-resistant Staphylococcus aureus is now an established community pathogen (CA-MRSA). At Texas Children's Hospital (TCH), about 75% of S. aureus isolates recovered from …
Baylor Role: Lead Sponsor
Completed
An ACE Inhibitor (Perindopril) or an Angiotensin Receptor Blocker (Candesartan) as a Treatment for Methamphetamine Dependence
Our preliminary data indicate that the ACE inhibitor perindopril can attenuate MA-induced drug craving, suggesting that perindopril should be evaluated as a treatment for MA dependence. Candesartan works similarly to …
Baylor Role: Lead Sponsor
Completed
Investigation of Cycloserine as a Smoking Cessation Treatment
See brief summary
Baylor Role: Lead Sponsor